NAFLD trial enrolls patients to assess effect of Basis on metabolic factors

Elysium Health completed enrollment for a clinical trial designed to evaluate the efficacy of Basis, a combination of the company’s proprietary nicotinamide riboside and pterostilbene, on liver fat accumulation in adults with nonalcoholic fatty liver disease, according to a press release.
The formulation of Basis was designed to increase oxidized nicotinamide adenine dinucleotide (NAD+) levels — a cofactor central to metabolism — and activate NAD-dependent sirtuins, which also regulate important physiological processes like lipid metabolism.
“There is evidence to show

Source link

Related posts

How to thrive in the inflamed gut


GNAI1 and GNAI3 Reduce Colitis-Associated Tumorigenesis in Mice by Blocking IL6 Signaling and Downregulating Expression of GNAI2


Prevalence of Germline Mutations Associated with Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy